"The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has developed guidance- external site for psychiatrists to help prevent adverse outcomes for patients prescribed MDMA and psilocybin. As the evidence base for these therapies is evolving, the guidance will be reviewed and updated as more data, and the experiences of psychiatrists and patients, become available. We will continue to work with the RANZCP to monitor the safety of these treatments outside clinical trial settings"
Good to see a governing body guidence in the protocols of regulated therapy procedures and the huge benefits these Clarion clinics aid and evolve set benchmark standards under the watchful eyes and feedback of RANZCP.
Definately be a steady approach at first as many industry eye world wide will be watching Australia. I wish the IHL/Clarion/Monarch team the very best of luck.
GLAH.